查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930071

全球性傳染病 (STD) 檢測市場：市場規模、市場佔有率、成長率、行業分析、依類型、應用和地區劃分的考慮因素以及未來預測 (2026-2034)

Sexually Transmitted Diseases Testing Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 162 Pages | 商品交期: 請詢問到貨日

價格

性傳染病 (STD) 檢測市場的成長因素

由於感染率上升、性健康意識增強以及政府主導的篩檢計畫擴大，全球性傳染病 (STD) 檢測市場正經歷顯著成長。根據 Fortune Business Insights 預測，該市場規模預計將在 2025 年達到 110.7 億美元，從 2026 年的 119.7 億美元增長到 2034 年的 239.5 億美元，在預測期（2026-2034 年）內複合年增長率 (CAGR) 為 9.0%。

北美地區在 2025 年佔全球市場主導地位，市佔率達 42.80%。這得益於完善的醫療基礎設施、公私合作以及政府主導的疾病檢測強化措施。

市場動態

性傳染病 (STD) 發生率的上升正在推動市場成長。

性傳染病由細菌、病毒或寄生蟲引起，經由性接觸或母嬰傳染。由於許多性傳染病沒有症狀，及時準確的診斷對於限制進一步感染至關重要。

根據全球估計：

  • 截至 2021 年，全球有 3,840 萬人感染 HIV。
  • 全球 15 至 49 歲族群中有 4.91 億人感染 HSV-2（2 型單純皰疹病毒）。
  • 披衣菌感染、淋病、梅毒和 HIV 的高盛行率持續推動對檢測試劑盒和診斷設備的需求。

某些人群中高風險性行為的增加、持續缺乏安全套使用以及性健康教育，進一步加劇了疾病負擔。

市場趨勢

從實驗室檢測到即時檢測 (POCT) 的轉變

性傳染病檢測市場最顯著的趨勢之一是從實驗室檢測逐步過渡到即時檢測 (POCT)。儘管實驗室檢測在2026年仍以78.33%的市場佔有率佔主導地位，但預計在預測期內，即時檢測（POC​​T）將以最高的複合年增長率增長。

即時偵測具有以下優點：

  • 更快的檢測結果
  • 更低的檢測成本
  • 更便捷的偵測途徑
  • 減少社會歧視和隱私顧慮

這些優勢正在加速醫療機構和患者在醫院、診所、藥房和家庭醫療保健機構中採用即時檢測解決方案。

市場區隔分析

依產品類型

  • 受高檢測量和持續需求的推動，試劑和試劑盒在2026年佔了79.32%的市場佔有率。
  • 由於診斷實驗室樣本處理量的增加，預計儀器市場將穩定成長。

依應用領域

  • 由於衣原體感染率高且檢測需求頻繁，衣原體檢測在2026年將佔24.47%的市場佔有率，成為市場主導。
  • 淋病、HIV和HPV檢測也佔了相當大的市場。
  • 由於常規篩檢有限，梅毒和生殖器皰疹的市佔率相對較低。

依最終使用者

  • 2026年，診斷中心憑藉著快速的服務和先進的診斷能力，佔了52.34%的市場佔有率，成為市場主導。
  • 醫院和診所緊隨其後，尤其是在新興國家。
  • 由於其隱私性和便利性優勢，居家檢測正受到越來越多的關注。

區域市場概況

  • 北美：預計到 2025 年，市場規模將達到 47.4 億美元，主要得益於公私合作和公眾意識提升項目。
  • 歐洲：先進的診斷基礎設施和數位化結果交付系統將推動市場成長。
  • 亞太地區：預計成長將達到最高的複合年增長率，主要得益於政府主導的各項舉措以及日本、中國和印度等國家公眾意識的不斷提高。
  • 拉丁美洲、中東和非洲：預期成長將較為溫和，這主要得益於政府和非政府組織主導的公眾意識提升計畫的增加。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家主要疾病流行情形（2025 年）
  • 主要行業趨勢
  • 主要國家和地區的監管概覽
  • 性傳染病 (STD) 檢測市場的技術進步
  • COVID-19 對全球性傳染病檢測市場的影響

第五章 全球性傳染病性傳染病 (STD) 檢測市場分析、洞察與預測 (2021-2034)

  • 市場分析、洞察與預測：依產品類型劃分
    • 設備
    • 試劑和試劑盒
  • 市場分析、洞察與預測：依應用劃分
    • 披衣菌感染
    • 梅毒
    • 生殖器皰疹
    • 淋病
    • 人類免疫缺乏病毒 (HIV)
    • 人類乳突病毒 (HPV)
    • 其他
  • 市場分析、洞察與預測：依檢測場所劃分
    • 臨床檢測
    • 即時偵測 (POC)
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院和診所
    • 診斷中心
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美性傳染病檢測市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲性傳染病（STD）檢測市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章：亞太地區性傳染病檢測市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲性傳染病（STD）檢測市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家國家/地區

第十章：中東與非洲性傳染病檢測市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家/地區
    • 南非
    • 其他中東和非洲國家/地區

第11章 競爭分析

  • 世界市場佔有率分析(2025年)
  • 企業簡介
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Becton, Dickinson and Company(BD)
  • Hologic, Inc.
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • bioMerieux, Inc.
  • Bio-Rad Laboratories, Inc.
  • DiaSorin Inc.
Product Code: FBI101095

Growth Factors of sexually transmitted diseases (STD) testing Market

The global sexually transmitted diseases (STD) testing market is witnessing strong growth due to rising infection rates, increasing awareness of sexual health, and expanding government-led screening initiatives. According to Fortunes Business Insights, the market was valued at USD 11.07 billion in 2025 and is projected to grow from USD 11.97 billion in 2026 to USD 23.95 billion by 2034, registering a CAGR of 9.10% during the forecast period (2026-2034).

North America dominated the global market in 2025, accounting for 42.80% market share, supported by robust healthcare infrastructure, public-private partnerships, and strong government initiatives to enhance disease detection.

Market Dynamics

Rising Incidence of STDs Driving Market Growth

Sexually transmitted diseases are caused by bacteria, viruses, or parasites and are transmitted through sexual contact or vertically from mother to child. Many STDs are asymptomatic, making timely and accurate diagnosis critical to limit further transmission.

According to global estimates:

  • 38.4 million people were living with HIV in 2021
  • 491 million people aged 15-49 had HSV-2 infection worldwide
  • High incidence rates of chlamydia, gonorrhea, syphilis, and HIV continue to increase demand for testing kits and diagnostic instruments

Increasing risky sexual behavior, lack of consistent condom usage, and limited sexual health education in certain populations are further contributing to the growing disease burden.

Market Trends

Shift from Laboratory Testing to Point-of-Care Testing

One of the most notable trends in the STD testing market is the gradual shift from laboratory-based testing to point-of-care testing (POCT). While laboratory testing dominated the market in 2026 with a share of 78.33%, POCT is expected to grow at the highest CAGR during the forecast period.

Point-of-care tests offer:

  • Faster turnaround time
  • Lower testing costs
  • Improved accessibility
  • Reduced stigma and confidentiality concerns

These benefits are encouraging healthcare providers and patients to adopt POCT solutions across hospitals, clinics, pharmacies, and homecare settings.

Segmentation Analysis

By Product Type

  • Reagents & kits dominated the market in 2026, holding 79.32% share, driven by high testing volumes and recurring demand.
  • Instruments are expected to grow steadily due to rising sample throughput in diagnostic laboratories.

By Application

  • Chlamydia testing led the market in 2026 with a 24.47% share, owing to its high prevalence and frequent testing requirements.
  • Gonorrhea, HIV, and HPV also accounted for significant market shares.
  • Syphilis and genital herpes held comparatively lower shares due to limited routine screening.

By End User

  • Diagnostic centers dominated the market in 2026 with 52.34% share, supported by faster service delivery and advanced diagnostic capabilities.
  • Hospitals & clinics followed, especially in emerging economies.
  • Home-based testing is gaining traction due to privacy and convenience benefits.

Regional Insights

  • North America: Market valued at USD 4.74 billion in 2025; strong growth driven by public-private partnerships and awareness programs.
  • Europe: Growth supported by advanced diagnostic infrastructure and digital result delivery systems.
  • Asia Pacific: Expected to grow at the highest CAGR, supported by government initiatives and rising awareness in countries such as Japan, China, and India.
  • Latin America & Middle East & Africa: Moderate growth due to increasing government and NGO-led awareness programs.

Competitive Landscape

The global STD testing market is fragmented, with major players including:

  • Abbott
  • F. Hoffmann-La Roche Ltd
  • bioMerieux
  • Bio-Rad Laboratories
  • Thermo Fisher Scientific
  • BD
  • Hologic, Inc.

These companies are focusing on R&D investments, strategic collaborations, and product launches to expand their global presence.

Conclusion

The global sexually transmitted diseases testing market is set for strong expansion from 2026 to 2034, driven by rising disease prevalence, growing awareness, and increasing adoption of point-of-care testing solutions. With the market expected to reach USD 23.95 billion by 2034, continued government initiatives, technological advancements, and improved accessibility to testing will play a crucial role in shaping market growth. Despite challenges such as stigma and reluctance toward testing, sustained efforts by healthcare authorities and industry players are expected to significantly strengthen STD detection and prevention worldwide.

Segmentation By Product Type, Application, Setting, End User, and Region

By Product Type * Instruments

  • Reagents & Kits

By Application * Chlamydia

  • Syphilis
  • Genital Herpes
  • Gonorrhea
  • Human Immunodeficiency Virus
  • Human Papillomavirus
  • Others

By Setting * Laboratory Testing

  • Point-of-Care

By End User * Hospital & Clinics

  • Diagnostic Centers
  • Others

By Region * North America (By Product Type, By Application, By Setting, By End User, By Country)

    • U.S.
    • Canada
  • Europe (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product Type, By Application, By Setting, By End User, By Country/ Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries, 2025
  • 4.2. Key Industry Developments
  • 4.3. Overview of Regulatory Scenario, By Key Countries/Regions
  • 4.4. Technological Advancements in Sexually Transmitted Diseases Testing Market
  • 4.5. Impact of COVID-19 on Global Sexually Transmitted Diseases Testing Market

5. Global Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Instruments
    • 5.1.2. Reagents & Kits
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Chlamydia
    • 5.2.2. Syphilis
    • 5.2.3. Genital Herpes
    • 5.2.4. Gonorrhea
    • 5.2.5. Human Immunodeficiency Virus
    • 5.2.6. Human Papillomavirus (HPV)
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Setting
    • 5.3.1. Laboratory Testing
    • 5.3.2. Point-of Care (POC)
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals and Clinics
    • 5.4.2. Diagnostic Centers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Instruments
    • 6.1.2. Reagents & Kits
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Chlamydia
    • 6.2.2. Syphilis
    • 6.2.3. Genital Herpes
    • 6.2.4. Gonorrhea
    • 6.2.5. Human Immunodeficiency Virus
    • 6.2.6. Human Papillomavirus (HPV)
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Setting
    • 6.3.1. Laboratory Testing
    • 6.3.2. Point-of Care (POC)
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Hospitals and Clinics
    • 6.4.2. Diagnostic Centers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Instruments
    • 7.1.2. Reagents & Kits
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Chlamydia
    • 7.2.2. Syphilis
    • 7.2.3. Genital Herpes
    • 7.2.4. Gonorrhea
    • 7.2.5. Human Immunodeficiency Virus
    • 7.2.6. Human Papillomavirus (HPV)
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Setting
    • 7.3.1. Laboratory Testing
    • 7.3.2. Point-of Care (POC)
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Hospitals and Clinics
    • 7.4.2. Diagnostic Centers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Instruments
    • 8.1.2. Reagents & Kits
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Chlamydia
    • 8.2.2. Syphilis
    • 8.2.3. Genital Herpes
    • 8.2.4. Gonorrhea
    • 8.2.5. Human Immunodeficiency Virus
    • 8.2.6. Human Papillomavirus (HPV)
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Setting
    • 8.3.1. Laboratory Testing
    • 8.3.2. Point-of Care (POC)
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Hospitals and Clinics
    • 8.4.2. Diagnostic Centers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Instruments
    • 9.1.2. Reagents & Kits
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Chlamydia
    • 9.2.2. Syphilis
    • 9.2.3. Genital Herpes
    • 9.2.4. Gonorrhea
    • 9.2.5. Human Immunodeficiency Virus
    • 9.2.6. Human Papillomavirus (HPV)
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Setting
    • 9.3.1. Laboratory Testing
    • 9.3.2. Point-of Care (POC)
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Hospitals and Clinics
    • 9.4.2. Diagnostic Centers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. Instruments
    • 10.1.2. Reagents & Kits
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Chlamydia
    • 10.2.2. Syphilis
    • 10.2.3. Genital Herpes
    • 10.2.4. Gonorrhea
    • 10.2.5. Human Immunodeficiency Virus
    • 10.2.6. Human Papillomavirus (HPV)
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Setting
    • 10.3.1. Laboratory Testing
    • 10.3.2. Point-of Care (POC)
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Hospitals and Clinics
    • 10.4.2. Diagnostic Centers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
    • 11.2.1. Abbott
      • 11.2.1.1. Overview,
      • 11.2.1.2. Product,
      • 11.2.1.3. SWOT Analysis,
      • 11.2.1.4. Recent Developments,
      • 11.2.1.5. Strategies,
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. F. Hoffmann-La Roche Ltd
      • 11.2.2.1. Overview,
      • 11.2.2.2. Product,
      • 11.2.2.3. SWOT Analysis,
      • 11.2.2.4. Recent Developments,
      • 11.2.2.5. Strategies,
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Becton, Dickinson and Company (BD)
      • 11.2.3.1. Overview,
      • 11.2.3.2. Product,
      • 11.2.3.3. SWOT Analysis,
      • 11.2.3.4. Recent Developments,
      • 11.2.3.5. Strategies,
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Hologic, Inc.
      • 11.2.4.1. Overview,
      • 11.2.4.2. Product,
      • 11.2.4.3. SWOT Analysis,
      • 11.2.4.4. Recent Developments,
      • 11.2.4.5. Strategies,
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Danaher Corporation
      • 11.2.5.1. Overview,
      • 11.2.5.2. Product,
      • 11.2.5.3. SWOT Analysis,
      • 11.2.5.4. Recent Developments,
      • 11.2.5.5. Strategies,
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Thermo Fisher Scientific Inc.
      • 11.2.6.1. Overview,
      • 11.2.6.2. Product,
      • 11.2.6.3. SWOT Analysis,
      • 11.2.6.4. Recent Developments,
      • 11.2.6.5. Strategies,
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. bioMerieux, Inc.
      • 11.2.7.1. Overview,
      • 11.2.7.2. Product,
      • 11.2.7.3. SWOT Analysis,
      • 11.2.7.4. Recent Developments,
      • 11.2.7.5. Strategies,
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Bio-Rad Laboratories, Inc.
      • 11.2.8.1. Overview,
      • 11.2.8.2. Product,
      • 11.2.8.3. SWOT Analysis,
      • 11.2.8.4. Recent Developments,
      • 11.2.8.5. Strategies,
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. DiaSorin Inc.
      • 11.2.9.1. Overview,
      • 11.2.9.2. Product,
      • 11.2.9.3. SWOT Analysis,
      • 11.2.9.4. Recent Developments,
      • 11.2.9.5. Strategies,
      • 11.2.9.6. financials (Based on Availability)

List of Tables

  • Table 01: Global Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 02: Global Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 03: Global Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Setting, 2021-2034
  • Table 04: Global Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 05: Global Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 06: North America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 07: North America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 08: North America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Setting, 2021-2034
  • Table 09: North America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 10: North America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 12: Europe Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 13: Europe Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Setting, 2021-2034
  • Table 14: Europe Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 15: Europe Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 16: Asia Pacific Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 17: Asia Pacific Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 18: Asia Pacific Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Setting, 2021-2034
  • Table 19: Asia Pacific Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 20: Asia Pacific Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 21: Latin America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 22: Latin America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 23: Latin America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Setting, 2021-2034
  • Table 24: Latin America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 25: Latin America Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 26: Middle East & Africa Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 27: Middle East & Africa Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 28: Middle East & Africa Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Setting, 2021-2034
  • Table 29: Middle East & Africa Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 30: Middle East & Africa Sexually Transmitted Diseases Testing Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034

List of Figures

  • Figure 01: Global Sexually Transmitted Diseases Testing Market Value Share (%), By Product Type, 2025 & 2034
  • Figure 02: Global Sexually Transmitted Diseases Testing Market Value Share (%), By Application, 2025 & 2034
  • Figure 03: Global Sexually Transmitted Diseases Testing Market Value Share (%), By Setting, 2025 & 2034
  • Figure 04: Global Sexually Transmitted Diseases Testing Market Value Share (%), By End User, 2025 & 2034
  • Figure 05: Global Sexually Transmitted Diseases Testing Market Value Share (%), By Region, 2025 & 2034
  • Figure 06: North America Sexually Transmitted Diseases Testing Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 07: North America Sexually Transmitted Diseases Testing Market Value Share (%), by Product Type, 2025
  • Figure 08: North America Sexually Transmitted Diseases Testing Market Value (USD billion), by Application, 2025 & 2034
  • Figure 09: North America Sexually Transmitted Diseases Testing Market Value Share (%), by Application, 2025
  • Figure 10: North America Sexually Transmitted Diseases Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 11: North America Sexually Transmitted Diseases Testing Market Value Share (%), by Setting, 2025
  • Figure 12: North America Sexually Transmitted Diseases Testing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 13: North America Sexually Transmitted Diseases Testing Market Value Share (%), by End User, 2025
  • Figure 14: North America Sexually Transmitted Diseases Testing Market Value (USD billion), by Country, 2025 & 2034
  • Figure 15: North America Sexually Transmitted Diseases Testing Market Value Share (%), by Country, 2025
  • Figure 16: Europe Sexually Transmitted Diseases Testing Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 17: Europe Sexually Transmitted Diseases Testing Market Value Share (%), by Product Type, 2025
  • Figure 18: Europe Sexually Transmitted Diseases Testing Market Value (USD billion), by Application, 2025 & 2034
  • Figure 19: Europe Sexually Transmitted Diseases Testing Market Value Share (%), by Application, 2025
  • Figure 20: Europe Sexually Transmitted Diseases Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 21: Europe Sexually Transmitted Diseases Testing Market Value Share (%), by Setting, 2025
  • Figure 22: Europe Sexually Transmitted Diseases Testing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 23: Europe Sexually Transmitted Diseases Testing Market Value Share (%), by End User, 2025
  • Figure 24: Europe Sexually Transmitted Diseases Testing Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 25: Europe Sexually Transmitted Diseases Testing Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 26: Asia Pacific Sexually Transmitted Diseases Testing Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 27: Asia Pacific Sexually Transmitted Diseases Testing Market Value Share (%), by Product Type, 2025
  • Figure 28: Asia Pacific Sexually Transmitted Diseases Testing Market Value (USD billion), by Application, 2025 & 2034
  • Figure 29: Asia Pacific Sexually Transmitted Diseases Testing Market Value Share (%), by Application, 2025
  • Figure 30: Asia Pacific Sexually Transmitted Diseases Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 31: Asia Pacific Sexually Transmitted Diseases Testing Market Value Share (%), by Setting, 2025
  • Figure 32: Asia Pacific Sexually Transmitted Diseases Testing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 33: Asia Pacific Sexually Transmitted Diseases Testing Market Value Share (%), by End User, 2025
  • Figure 34: Asia Pacific Sexually Transmitted Diseases Testing Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 35: Asia Pacific Sexually Transmitted Diseases Testing Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 36: Latin America Sexually Transmitted Diseases Testing Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 37: Latin America Sexually Transmitted Diseases Testing Market Value Share (%), by Product Type, 2025
  • Figure 38: Latin America Sexually Transmitted Diseases Testing Market Value (USD billion), by Application, 2025 & 2034
  • Figure 39: Latin America Sexually Transmitted Diseases Testing Market Value Share (%), by Application, 2025
  • Figure 40: Latin America Sexually Transmitted Diseases Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 41: Latin America Sexually Transmitted Diseases Testing Market Value Share (%), by Setting, 2025
  • Figure 42: Latin America Sexually Transmitted Diseases Testing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 43: Latin America Sexually Transmitted Diseases Testing Market Value Share (%), by End User, 2025
  • Figure 44: Latin America Sexually Transmitted Diseases Testing Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 45: Latin America Sexually Transmitted Diseases Testing Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 46: Middle East & Africa Sexually Transmitted Diseases Testing Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 47: Middle East & Africa Sexually Transmitted Diseases Testing Market Value Share (%), by Product Type, 2025
  • Figure 48: Middle East & Africa Sexually Transmitted Diseases Testing Market Value (USD billion), by Application, 2025 & 2034
  • Figure 49: Middle East & Africa Sexually Transmitted Diseases Testing Market Value Share (%), by Application, 2025
  • Figure 50: Middle East & Africa Sexually Transmitted Diseases Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 51: Middle East & Africa Sexually Transmitted Diseases Testing Market Value Share (%), by Setting, 2025
  • Figure 52: Middle East & Africa Sexually Transmitted Diseases Testing Market Value (USD billion), by End User, 2025 & 2034
  • Figure 53: Middle East & Africa Sexually Transmitted Diseases Testing Market Value Share (%), by End User, 2025
  • Figure 54: Middle East & Africa Sexually Transmitted Diseases Testing Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 55: Middle East & Africa Sexually Transmitted Diseases Testing Market Value Share (%), by Country/Sub-Region, 2025